Overview of Current Status of Checkpoint Inhibitors in NSCLC
Clinical Application of Immune Checkpoint Inhibitors for NSCLC
- A case-based discussion exploring the use of checkpoint inhibitors in different patients with NSCLC, using CCO’s decision support tool for NSCLC
Late-Stage Developments in Immunotherapy for NSCLC
Expert-Led Discussion With Meeting Attendees of Challenging Cases From Their Practices
Date / Time
Heather Wakelee, MD
Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine at the University of Pennsylvania
Jamie E. Chaft, MD
Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Melissa L. Johnson, MD
Associate Director, Lung Cancer Research
Sarah Cannon Research Institute
Daniel Morgensztern, MD
Division of Oncology
Department of Medicine
St Louis, Missouri
Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
Thomas Stinchcombe, MD
Professor of Medicine
Department of Medicine
Duke University School of Medicine
Member, Duke Cancer Institute
Durham, North Carolina
Anne S. Tsao, MD
Division of Cancer Medicine
Department of Thoracic/Head and Neck Medical Oncology
Department of Mesothelioma Program
The University of Texas MD Anderson Cancer Center
The goal of this activity is to improve participants’ competence and performance in applying immune checkpoint inhibitors in the treatment of patients with non-small-cell lung cancer.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer.
- Plan treatment strategies for patients with NSCLC and disease progression on or after platinum-containing chemotherapy based on available data, treatment guidelines, and expert recommendations
- Compare immune checkpoint inhibitors as second-line therapy for patients with metastatic NSCLC
- Evaluate the therapeutic impact of PD-1 inhibition as first-line treatment of patients with advanced NSCLC and high PD-L1 expression
- Identify patients with advanced NSCLC who may benefit from immune checkpoint inhibitor therapy
- Manage immune-related adverse events in patients with advanced NSCLC on checkpoint inhibitor therapy
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Medical Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-059-L01-P)
Type of Activity: Application
Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.